OrthogenRx Launches TriVisc in the US

OrthogenRx commenced U.S. launch of TriVisc® sodium hyaluronate for the treatment of knee osteoarthritis pain in a 3-injection regimen.

The formulation has received regulatory clearance in 63 countries ex-U.S. and been administered in over 35 million doses worldwide. The company claims it to be the lowest-priced 3-injection hyaluronic acid...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us